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SUMMARY Topical antibiotics are frequently introduced in therapy 
by various specialists, e.g., dermatologists-venereologists, ENT 
specialists, proctologists, ophthalmologists, and others. In dermatology, 
topical antibiotics are used in the treatment of superficial inflammatory 
skin lesions, acne and rosacea. These agents are also used in the 
prevention of inflammatory lesions after surgical and corrective 
procedures. Long-term and uncontrolled application of topical 
antibiotics, on the skin with impaired protective barrier in particular, 
implies a risk for the development of hypersensitivity to these agents. 
Considering the very wide utilization of these agents, hypersensitivity 
to topical antibiotics poses a major problem worldwide. The groups at 
a high risk of contact sensitivity to topical antibiotics include patients 
with chronic venous insufficiency, chronic ulcers and chronic otitis 
externa, as well as individuals at occupational exposure to antibiotics, 
e.g., human medicine and veterinary medicine professionals, 
pharmaceutical industry workers, cattle breeders, etc. When long-
term therapy fails to result in improvement in the above mentioned 
chronic states, the possibility of allergic reactions to topical agents 
should be taken in consideration. Cross-sensitivity, which is frequently 
associated with the use of topical aminoglycoside antibiotics, poses a 
significant problem.
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INTRODUCTION
 Topical antibiotics are frequently used in der-
matology and venereology, ENT, proctology and 
ophthalmology routine. In dermatology, these 
agents are mostly used in the treatment of superfi-
cial inflammatory skin lesions, acne and rosacea, 
and for prevention of inflammatory lesions fol-
lowing surgical and corrective procedures. In the 
treatment of chronic ulcers, topical antibiotics are 
applied as target therapy and over a limited period 
of time, however, their use may frequently be com-
promised and result in side effects.
 Antibiotics are frequently identified with other 
anti-infective agents, primarily antiseptics, which 
also exert bactericidal action. The action of anti-
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septics implies denaturation and destruction of the 
microorganism cell wall, which is accompanied by 
unselective destruction of host cells. Unlike anti-
septics, antibiotics act upon the growth and func-
tion of bacterial cell modifying its metabolism (1).
 Topical antibiotics are perceived as “harmless” 
agents, thus being occasionally uncritically pre-
scribed by physicians. Their uncontrolled use by 
patients on their own is by no means rare practice. 
Therefore, the development of resistance to topi-
cal antibiotics has been recognized as a growing 
problem (2).
 Long-term and uncontrolled use of topical an-
tibiotics, especially their application onto impaired 
skin, entails the risk of sensitivity to these agents. 
Although rare, this phenomenon poses a signifi-
cant problem considering the widespread use of 
these topical agents. Literature data point to some 
patient groups at an increased risk of sensitization 
to topical antibiotics, i.e. patients with chronic ve-
nous insufficiency, venous ulcers and chronic otitis 
externa. In addition, the risk of sensitization is also 
increased in individuals at professional exposure 
to antibiotics, e.g., human medicine and veterinary 
medicine professionals, cattle breeders, and work-
ers in pharmaceutical industry.
EPIDEMIOLOGY
 There are no data on the prevalence of aller-
gic contact dermatitis (ACD) to topical antibiotics 
in the general population. The only data available 
derive from allergologic testing in patients with the 
symptoms of ACD. According to the Mayo Clinic 
Contact Dermatitis Group report for the 1998-2000 
period, 69.3% of study subjects exhibited at least 
one positive reaction on skin tests. Two antibiotic 
agents were among the first ten allergens, i.e. 
neomycin sulfate as third and bacitracin at a lower 
place (3). Similar data have also been reported 
by the North American Contact Dermatitis Group, 
where neomycin sulfate accounted for 11.6% and 
bacitracin for 7.9% of all positive reactions (4). In 
1993, Lipozenčić et al. demonstrated progressive 
increase in the rate of hypersensitivity to neomycin 
sulfate over a 3-year period (1990-1992), from 5% 
in 1990, 7.69% in 1991 to 10.18% in 1992 (5).
HIGH-RISK GROUPS
 The risk of sensitization to various topical agents 
is increased in patients with chronic venous insuf-
ficiency and venous ulcers due to impaired skin 
integrity and usually long-term application of these 
agents. According to data from a Canadian study 
conducted in 2004, as many as 63% of patients 
with venous ulcer in their previous or current his-
tory showed at least one positive reaction to stan-
dard or additional series of allergens on skin test-
ing (6). In a similar study from Scotland there were 
68% of positive reactions to at least one allergen 
(7), which is consistent with the mean prevalence 
across European countries, ranging from 40% to 
82.5% (6).
 Sensitization most frequently develops to 
agents used in patient treatment, varying accord-
ing to habits and recommendations in different 
countries. In Far East countries, there is a high 
rate of sensitization to traditional topical Chinese 
medicaments, which are widely used there (8). 
Concerning additional set of allergens, a study 
carried out in Slavonski Brod, Croatia revealed the 
highest proportion of positive reactions to cortico-
steroid agents, lanolin and bepanthen (9).
 Topical antibiotics are very often recommended 
postoperatively as a preventive measure, even in 
minor operative procedures. A study from 1992 
(10) demonstrated the postoperative application of 
topical antibiotics onto the wound to increase the 
risk of sensitization and allergic reactions to these 
agents. The study included 215 patients recom-
mended postoperative therapy with topical anti-
biotics. Nine patients developed ACD symptoms 
instead of wound healing. Seven of these nine pa-
tients gave their consent for allergologic testing. 
Of these, skin test was positive for neomycin and 
bacitracin in five and four patients, respectively. 
All patients with positive reaction to bacitracin also 
exhibited positive reaction to neomycin.
 Sensitization to topical antibiotics is quite com-
mon in patients with chronic inflammatory ear le-
sions. A British study from 2004 (11) proved con-
tact sensitivity to medicaments in as many as 25% 
of patients with long-standing inflammatory ear le-
sions. Positive reaction to neomycin was recorded 
in 76%, framycetin in 62% and gentamicin in 18% 
of patients, along with a high rate of cross-sen-
sitivity among these antibiotics. The same study 
describes a declining rate of sensitization during 
the past 17 years, supported by another British 
study from 1982, where the rate of sensitization to 
topical antibiotics in patients with chronic inflam-
matory ear lesions was as high as 35%. Allergic 
reaction was most commonly caused by neomy-
cin, framycetin, clioquinol and gentamicin (12).
 The individuals at frequent or even daily occu-
pational exposure to antibiotics are at an increased 
risk of developing hypersensitivity to these agents. 
Gorgievska Sukarovska et al.     Acta Dermatovenerol Croat
Allergic contact dermatitis to antibacterial agents      2009;17(1):70-76
ACTA DERMATOVENEROLOGICA CROATICA
72
This group at risk includes healthcare profes-
sionals, veterinary medicine professionals, cattle 
breeders, and in particular workers in pharmaceu-
tical industry directly involved in drug manufacture, 
which is discussed below.
MOST WIDELY USED ANTIBIOTICS
	 Aminoglycoside antibiotics are a group of 
antibiotics with a similar chemical structure. They 
bind to ribosome 30S subunit, thus preventing 
protein synthesis in bacterial cell (2). All antibiot-
ics from this group except for streptomycin con-
tain deoxystreptamine group, which is responsible 
for the high rate of cross-sensitivity among them 
(13,14). Neomycin, butyrosine and paramomycin 
contain neosamine group and 4,5-di-oxi substi-
tuted deoxystreptamine group (15), thus their rate 
of cross-sensitivity being up to 97%. Because of 
different chemical structure of streptomycin (14) 
and spectinomycin (16), cross-sensitivity with 
other aminoglycoside antibiotics has not been de-
scribed.
 Neomycin is the best known representative of 
this group. It is a product of Streptomyces fradiae 
fermentation and acts against gram-negative bac-
teria. Commercial preparation is a combination of 
neomycin B and neomycin C, whereas framycetin, 
which is available in Canada and some European 
countries, is pure neomycin B (2). The first aller-
gic reaction to neomycin was reported as early as 
1952 (15). In a retrospective German study from 
2005 for the 1998-2003 period, skin test to neomy-
cin was positive in 2.5% of 47,559 study subjects 
(17), while a British study reported a 3.5% rate of 
sensitivity to neomycin in 2002 (18).
 Gentamicin is another topical antibiotic that is 
widely used in Croatia. It is a product of Micro-
monospora purpurea fermentation. Its antibacte-
rial spectrum and mechanism of action are very 
similar to other antibiotics of this group (2). The 
prevalence of contact sensitivity to gentamicin in 
patients with chronic venous insufficiency and ve-
nous ulcer is 10%, and in those with chronic otitis 
externa 7% (15).
 Tobramycin is frequently used in ophthalmo-
logic preparations in the form of drops and oint-
ment. It is associated with a high rate of cross-
sensitivity to neomycin, ranging from 25% to 65%; 
however, allergic reactions to tobramycin with 
negative reaction to neomycin have also been 
described (14). A case of fixed exanthema that 
developed 48 hours after intramuscular adminis-
tration of tobramycin in a female patient exhibiting 
positive skin reaction to neomycin and negative 
reaction to tobramycin was reported in 2006 (19).
 Streptomycin is an aminoglycoside antibiotic 
that is not used as topical agent due to its high 
sensitization potential. Therefore, hypersensitivity 
to streptomycin occurs as an occupational disease 
in workers directly exposed to it. The first cases of 
streptomycin sensitivity were described in 1947, 
only three years after its synthesis, in nurses in 
daily contact with streptomycin intended for the 
treatment of tuberculosis patients (20). ACD 
to streptomycin has been described in a cattle 
breeder working on the farm and coming in close 
contact with various antibiotic preparations. Skin 
testing to various antibiotics was only positive to 
streptomycin. The man had suffered from chronic 
hyperkeratotic dermatitis with many painful rhaga-
des for ten years, with almost complete regression 
while on vacation (20). 
 Polypeptide antibiotics
 Bacitracin is a cyclic polypeptide antibiotic, a 
product of the bacterium Bacillus subtilis. It inter-
feres with bacterial cell wall synthesis. It is available 
as pure bacitracin and bacitracin zinc. The latter is 
important for a decreased sensitization potential. 
Bacitracin is effective against gram-positive bacte-
ria, whereas gram-negative bacteria are resistant 
to this agent (2). Therefore its use with neomycin 
was an ideal combination covering a broad spec-
trum of bacteria. However, their large-scale con-
current application has led to sensitization to both 
agents irrespective of their different structure. In 
contrast to cross-sensitization to aminoglycoside 
antibiotics, which develops due to similar chemical 
structure, in case of co-sensitization simultaneous 
exposure plays a major role, mostly when topical 
agents are applied upon impaired skin (21). The 
occurrence of ACD upon the application of a com-
bined topical preparation (neomycin, bacitracin 
and corticosteroid) for trauma has been reported. 
Skin test was positive to all the three agents (22).
 Polymyxin B is produced by the bacterium 
Bacillus polymyxa. It destroys bacterial cell and 
acts as cationic detergent. Polymyxin B is effec-
tive against many gram-negative bacteria includ-
ing Pseudomonas aeruginosa, Enterobacter and 
Escherichia coli (2).
 Mupirocin is produced by Pseudomonas fluo-
rescens. It inhibits bacterial protein synthesis and 
reversibly binds to isoleucyl-tRNA synthetase. Mu-
pirocin is effective against gram-positive bacteria, 
i.e. Staphylococcus aureus and Streptococcus 
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pyogenes, thus being the antibiotic of choice in the 
treatment of impetigo contagiosa (2). Otherwise, 
mupirocin has low allergenic potential and be-
cause of its specific chemical structure no cases 
of cross-reaction with other antibiotics have been 
reported (15).
 Chloramphenicol was initially isolated from 
Streptomyces venezuelae; owing to its simple 
chemical structure, the agent has also been pro-
duced synthetically. Chloramphenicol inhibits bac-
terial protein synthesis and binds to ribosomal 50S 
subunit (2). It is used in ophthalmologic prepara-
tions and in combination with collagenase clos-
tridiopeptidase in the management of wounds and 
ulcers where enzymatic cleansing is required. Two 
cases of ACD associated with the application of 
chloramphenicol in the area of venous ulcer have 
been described. Skin test was positive to chloram-
phenicol alone, but negative to collagenase (23).
 Antibacterial agents used in the manage-
ment of acne
 Erythromycin is a macrolide antibiotic that is 
primarily used as topical preparation in the treat-
ment of acne. It is produced by fermentation of 
the bacterium Streptomyces erythreus. It inhibits 
bacterial protein synthesis by binding to ribosome 
50S subunit. Erythromycin has a broad spectrum 
of action including gram-positive and gram-nega-
tive bacteria.
 Clindamycin is a semisynthetic product, a lin-
comycin derivative, with a mechanism of action 
similar to erythromycin, which is also widely used 
in the treatment of acne (2). According to literature 
data, these two agents have a low allergenic po-
tential, with only few cases of contact sensitization 
reported (15).
 Benzoyl peroxide is primarily used in the 
management of acne. Cases of sensitivity follow-
ing topical application are rarely described; how-
ever, irritative reactions are quite common. Ben-
zoyl peroxide is more significant as a professional 
allergen in medicine and dental medicine profes-
sionals and in plastic manufacture workers. ACD 
has been reported in an orthopedic technician at 
daily occupational exposure to immobilization ma-
terials. Skin test was positive to benzoyl peroxide 
and to the gel used for immobilization material 
fastening that contained benzoyl peroxide (24). 
Benzoyl peroxide is also added as an adjuvant to 
prosthetic materials used in dental medicine. In a 
study from 2004 assessing contact allergy to con-
stituent and adjuvant prosthetic materials, benzoyl 
peroxide accounted for as many as 7.69% of all 
positive skin test reactions (25).
 Metronidazole is a synthetic nitroimidazole 
that is primarily used in the treatment of rosa-
cea. Oral formulation is used in the management 
of protozoa and anaerobes. Cross-reaction has 
been reported for tioconazole (phenetyl imidazole) 
with bifonazole (phenmethyl imidazole) and met-
ronidazole (nitroimidazole) without previous expo-
sure to bifonazole and metronidazole. Therefore, 
in case of contact sensitivity to any of imidazoles, 
skin testing to other imidazoles is recommended 
for potential cross-reaction (26). In the treatment 
of rosacea, sensitivity reactions to metronidazole 
are rare (27). Such reactions have also been de-
scribed upon intravaginal application of metroni-
dazole vaginal tablets. Development of systemic 
reaction to oral metronidazole has been described 
in a female patient that failed to report previous 
local erythema following vaginal application of the 
agent (28). 
 Allergic contact dermatitis to systemic anti-
biotics
 In most cases, ACD to systemic antibiotics oc-
curs as occupational disease, mostly in human 
medicine and veterinary medicine professionals, 
farmers and cattle breeders, and in pharmaceuti-
cal industry workers. A study from 1994 revealed a 
decline in the rate of penicillin sensitivity in nurses 
from Warsaw. The rate of sensitization of as high 
as 9.77% recorded during the 1981-1985 period 
decreased to 0.7% in the 1996-1998 period. This 
decline was explained by the reduced penicillin 
exposure of medical professionals and the grow-
ing use of semisynthetic penicillins (29).
 There also are reports on occupational ACD 
to cephalosporins. A study from 1997 included 
14 nurses and four medical technicians with ACD 
symptoms, that were daily exposed to various 
cephalosporins at their work places. Skin test 
positive to at least one cephalosporin was record-
ed in seven study subjects, whereas one subject 
showed positive reaction to penicillin. One patient 
was simultaneously positive on patch tests with 
cephalosporins having in common amino-thiazo-
lyl-alkoxy-iminicol group. In the other six patients, 
all the cephalosporins that gave positive results 
have in common tetrazolic ring. There was no 
cross-reaction with the β-lactam ring containing 
penicillin (30).
 Due to their daily and long-term contact with 
antibiotics, workers in pharmaceutical industry, 
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those involved in the very process of manufacture 
in particular, are a high-risk group for the develop-
ment of ACD to antibiotics. A series of cases of oc-
cupational ACD to azithromycin in workers directly 
involved in the process of azithromycin synthesis 
were described in 2007. The appearance of ery-
thema, edema and vesicles on the hands, face, 
neck, shoulders and legs, i.e. symptoms charac-
teristic of airborne dermatitis, was observed in 
seven of 21 workers. Three of them also suffered 
from respiratory disturbances in the form of rhini-
tis, rhinoconjunctivitis and dyspnea, whereas one 
female developed generalized urticaria. Skin test-
ing demonstrated sensitization to azithromycin in 
four workers, and also to a number of azithromy-
cin precursors in two workers (31). 
 ACD to antibiotics intended for oral administra-
tion may develop in patients, mostly those with ve-
nous ulcers that used to take these agents uncon-
ventionally, applying the powder from the capsules 
directly onto the ulcer. Cases of ACD upon the use 
of cloxacillin and cephalexin capsules have been 
described (15).
CLINICAL MANIFESTATIONS OF 
ALLERGIC REACTION TO TOPICAL 
ANTIBIOTICS
 Besides ACD as type IV hypersensitivity reac-
tion according to Gell and Coombs classification 
as the most common manifestation, type I hy-
persensitivity reactions ranging from contact ur-
ticaria through anaphylactic reactions have been 
described with the use of topical antibiotics. The 
application of topical antibiotics directly onto the 
wound or the skin with impaired protective barrier 
is considered a risk factor for the development of 
immediate hypersensitivity. According to a study 
from 2007, 44 anaphylactic reactions due to the 
application of topical antibiotics were reported to 
Federal Institute of Drugs and Medical Devices in 
Germany during the 1998-2006 period. Upon data 
processing, 28 cases were identified as anaphy-
lactic reactions. In 8 (29%) cases, anaphylaxis was 
induced by antibiotics or antiseptics. The same 
study explored literature data and found topical 
antibiotics and antiseptics to be responsible for as 
many as 73% of anaphylactic reactions following 
application of topical preparations. Data on the oc-
currence of Stevens-Johnson syndrome were also 
processed in this study; however, no case of Ste-
vens-Johnson syndrome associated with the use 
of topical antibiotic had yet been reported (32).
 Systemic contact dermatitis occurs upon sys-
temic exposure to the allergen to which the patient 
has previously developed ACD. Systemic contact 
dermatitis is considered to be a form of delayed, 
T cell-mediated reaction. Hypersensitivity to met-
als, nickel in particular, is a prototype of such a 
reaction. However, antibiotics are responsible 
for it in a great number of cases (33). A peculiar 
clinical form of systemic contact-type dermatitis is 
so-called baboon syndrome with a characteristic 
clinical picture (and named after it) of sharply de-
marcated symmetric erythema in the gluteal and 
flexural regions but without systemic symptoms. 
According to a study from 2004, the culprits were 
antibiotics, mostly amoxicillin, cephalosporins and 
ampicillin, in 42 of 100 cases of the syndrome de-
scribed (34).
CONCLUSION
 Long-term use of topical antibiotics, especially 
upon the skin of deranged integrity and impaired 
protective barrier, is associated with the risk of 
sensitization and allergic reactions. Patients with 
chronic venous insufficiency and venous ulcers, 
chronic otitis externa, and chronic eczematous 
diseases are at a high risk and potential develop-
ment of allergic reactions to topical agents should 
be considered in these chronic patient groups, 
especially when prolonged therapy fails to lead 
to improvement. Skin testing that should include 
additional allergen series is the gold standard to 
make an accurate diagnosis, however, the possi-
bility of cross-sensitivity should be taken in consid-
eration.
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